GSK secures rights to Syndivia’s ADC asset for prostate cancer
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
The Ultimate Guide to Preventing Home Disasters Your home is more than a place where you sleep. It’s where you build memories, raise your …
Redefining Urban Living Through Harmony Between City and Nature The idea of "Tbilisi Acres" was born out of a vision to create a modern ur…
In Review: Big-Ass Sword by Andreas Butzbach Luke Williams reviews Andreas Butzbach's first graphic novel published in English.
ServiceNow and Nvidia Introduce Open-Source Model for Enhanced Security Concerned about your business's data security? Apriel 2.0 is desig…
California High School Overhaul California is looking to reform high school learning, and one school is paving the way. CART High, …
Cygnet Energy Enters into Agreement to Acquire Kiwetinohk Energy Corp. Cygnet Energy Ltd., a private exploration and production company, h…
Plant Secret Language Plants have a secret language that scientists are only now starting to decipher. Signals from the plant cell …
Novartis Q3 Performance Novartis' Q3 performance was driven by fast growth in recently label-expanded drugs, despite generic competition a…
Wayfair Q3 Earnings Snapshot Wayfair Inc. reported a loss of $99 million in its third quarter, with a loss of 76 cents per share. E…
Elon Musk's xAI Launches Grok-powered 'Grokipedia' Encyclopedia Elon Musk’s xAI startup has launched Grokipedia, a new open-source encyclo…